{"id":586152,"date":"2026-07-14T00:00:00","date_gmt":"2026-07-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0031-2026-biopharma-chronic-obstructive-pulmonary-disease-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-07-14T00:00:00","modified_gmt":"2026-07-14T00:00:00","slug":"cutrim0031-2026-biopharma-chronic-obstructive-pulmonary-disease-current-treatment-current-treatment-physician-insights","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0031-2026-biopharma-chronic-obstructive-pulmonary-disease-current-treatment-current-treatment-physician-insights\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Chronic Obstructive Pulmonary Disease (EU5)"},"content":{"rendered":"<p>The treatment landscape for chronic obstructive pulmonary disease (<abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>) has significantly evolved in the past few years. A plethora of <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> treatments are available in the <abbr data-abbreviation-entity=\"6092\" title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>. These include long-acting inhalers such as long-acting beta2-agonist (<abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>) \/ long-acting muscarinic antagonist (<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>) \/ inhaled corticosteroid (<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr>) fixed-dose combinations (<abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s) (i.e., Trimbow, Trelegy and Trixeo), which are rapidly gaining traction in the <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> market, complementing existing <abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>, <abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>, and <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s. More recently, the approval of biologics such as Dupixent and Nucala has further expanded treatment choices and increased the complexity of physicians\u2019 prescribing decisions. In this report, we offer insight into <abbr data-abbreviation-entity=\"6092\" title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> pulmonologists\u2019 prescribing patterns, attitudes and perceptions, and current and anticipated use of various products. We also examine the perceived advantages and disadvantages of key market players, all of them essential to anticipate shifts in frontline practice.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which drugs are the patient-share leaders in different lines of therapy? How are the various <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s and biologics positioned in the <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> treatment algorithm?<\/li>\n<li>What are the most influential drivers of treatment selection, and under which scenarios do physicians prescribe Dupixent and Nucala?<\/li>\n<li>How long do patients stay on a specific therapy? What factors drive therapy discontinuation and switching?<\/li>\n<li>How have pulmonologists\u2019 prescribing behaviors changed in the past year? What changes do they anticipate in the coming year?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Through survey data from <abbr data-abbreviation-entity=\"6092\" title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand&#8217;s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n<p><b>Publication date: <\/b>July 2026<\/p>\n<p><b>Geography: <\/b>France, Germany, Italy, Spain, United Kingdom<\/p>\n<p><strong>Primary research:<\/strong> Survey of 250 European pulmonologists<\/p>\n<p><strong>Key drugs covered: <\/strong>Tiotropium, Anoro, Ultibro, Spiolto, Symbicort, Relvar, Trimbow, Trixeo, Trelegy, Dupixent, Nucala<\/p>\n<p><strong>Key analyses<\/strong><\/p>\n<ul>\n<li>Factors influencing disease management and treatment decisions<\/li>\n<li>Drivers and constraints of treatment selection<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares<\/li>\n<li>Rationale for changes in treatment approach<\/li>\n<li>Physician insight on persistency and compliance<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-586152","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-therapy-areas-respiratory","biopharma-product-current-treatment","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/586152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=586152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}